Influenza virus vaccine using nanometer emulsion as adjuvant and method for preparing same

An influenza virus and nanoemulsion technology, applied in antiviral agents, medical preparations containing active ingredients, pharmaceutical formulations, etc., can solve the problem of limited immunogenicity enhancement of vaccines, and achieve enhanced bioavailability and dosage. Small, fluid effect

Inactive Publication Date: 2010-09-29
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In order to overcome the disadvantages of existing vaccine adjuvants such as adverse reactions and relatively limited enhancement of vaccine immunogenicity, the present invention provide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Influenza virus vaccine using nanometer emulsion as adjuvant and method for preparing same
  • Influenza virus vaccine using nanometer emulsion as adjuvant and method for preparing same
  • Influenza virus vaccine using nanometer emulsion as adjuvant and method for preparing same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] A. Dilute the stock solution of influenza virus vaccine with water for injection to a hemagglutinin concentration of 30 μg / (strain.ml), to obtain the diluted influenza virus vaccine;

[0034] B, prepare materials according to the following mass ratio: 10g of diluted influenza virus vaccine, 50g of isopropyl myristate, 20g of 1,2-propanediol, and 20g of Tween80;

[0035] C. Add 20g Tween80 and 20g 1,2-propylene glycol into the mixing and stirring bottle, and continue to stir at a temperature of 60°C. The rotating speed is maintained at 50 rpm, and then 50g isopropyl myristate is added to obtain a mixed solution;

[0036] D. Slowly drop the diluted influenza virus vaccine of step A into the above mixed solution, while maintaining the rotation speed at 50 rpm, stir until the liquid is transparent, and obtain the influenza virus vaccine with nanoemulsion as adjuvant.

[0037] The prepared influenza virus vaccine is tested as follows: 1. Detected by a Malvern particle size d...

Embodiment 2

[0039] A, dilute the stock solution of influenza virus vaccine with water for injection to a hemagglutinin concentration of 15 μg / (strain.ml), to obtain the diluted influenza virus vaccine;

[0040] B, prepare raw materials according to the following mass ratio: 30g diluted influenza virus vaccine, 30g soybean oil for injection, 20g polyethylene glycol 400, 12g Tween80, 8g Span80;

[0041] C. Add 12g Tween80 and 8g Span80 and 20g Polyethylene Glycol 400 in the mixing and stirring bottle, keep stirring at a temperature of 20°C, and keep the rotating speed at 500 rpm, then add 30g soybean oil for injection to obtain a mixture;

[0042] D. Slowly drop the diluted influenza virus vaccine into the above mixture, while maintaining the rotating speed at 500 rpm, stir until the liquid is transparent, and obtain the influenza virus vaccine with the nanoemulsion as an adjuvant.

[0043] The prepared influenza virus vaccine is tested as follows: 1. Detected by a Malvern particle size det...

Embodiment 3

[0045] A. Dilute the influenza virus vaccine stock solution with water for injection to a hemagglutinin concentration of 50 μg / (strain.ml);

[0046] B, prepare raw materials according to the following mass ratio: 20g diluted influenza virus vaccine, 20g soybean oil for injection, 40g polyethylene glycol 400, 8g Tween80, 12g Span80;

[0047] C. Add 8g Tween80, 12g Span80, 40g Polyethylene Glycol 400 to the mixing and stirring bottle, keep stirring at 40°C, keep the rotating speed at 200 rpm, then add 20g soybean oil for injection to obtain the mixture;

[0048] D. Slowly drop the diluted influenza virus vaccine into the above mixture while maintaining the rotating speed at 200 rpm, and stir until the liquid is transparent to obtain the influenza virus vaccine with the nanoemulsion as an adjuvant.

[0049] The prepared influenza virus vaccine is tested as follows: 1. Detected by a Malvern particle size detector, the particle size range is 18.906~24.854nm, qualified; 2. Through 400...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention provides an influenza virus vaccine using nanometer emulsion as an adjuvant and a method for preparing the same. The influenza virus vaccine consists of the following components in percentage by mass: 1 to 30 percent of diluted influenza virus vaccine, 1 to 50 percent of oil phase, 20 to 70 percent of emulsifying agent and 20 to 70 percent of auxiliary emulsifying agent. In the influenza virus vaccine using the nanometer emulsion as the adjuvant, the adjuvant, namely the nanometer emulsion, has the advantages of little toxicity, mild properties, obvious solubility-enhancing effect on medicaments, good fluidity, extremely low irritation on bodies and the like, so that the immunization effect of the influenza virus vaccine is greatly improved; compared with the adjuvant-free influenza virus vaccine, the influenza virus vaccine of the invention has the advantages of small dosage and high bioavailability; compared with other influenza virus vaccines using the adjuvant, the influenza virus vaccine of the invention has the advantages of greatly improving bioavailability, lowering irritation, reducing adverse reactions, prolonging vaccine-releasing time, improving the targeting property of the vaccine, reducing an attrition rate and the like.

Description

technical field [0001] The invention relates to an influenza virus vaccine, in particular to an influenza virus vaccine with nanoemulsion as an adjuvant and a preparation method thereof, belonging to the field of biotechnology. technical background [0002] Influenza, referred to as influenza, is an acute respiratory infection caused by influenza virus, mainly through droplets or close contact between people. Influenza is highly contagious, spreads rapidly, and mutates rapidly. It can cause a variety of serious complications and lead to high mortality. It has posed a serious threat to public health security around the world. According to the epidemic characteristics of influenza, it can be divided into seasonal influenza and pandemic influenza. Seasonal influenza occurs mostly in winter, and the virus that causes seasonal influenza usually already exists in the population, and it is not the first contact with the human immune system, so it is less harmful. However, once th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/39A61K39/145A61P31/16
Inventor 李映波毕湖冰陈芹芹
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap